0001799191-23-000048.txt : 20230918
0001799191-23-000048.hdr.sgml : 20230918
20230918080015
ACCESSION NUMBER: 0001799191-23-000048
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 15
CONFORMED PERIOD OF REPORT: 20230915
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20230918
DATE AS OF CHANGE: 20230918
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncology Institute, Inc.
CENTRAL INDEX KEY: 0001799191
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39248
FILM NUMBER: 231260124
BUSINESS ADDRESS:
STREET 1: 18000 STUDEBAKER RD
STREET 2: SUITE 800
CITY: CERRITOS
STATE: CA
ZIP: 90703
BUSINESS PHONE: 562-735-3226
MAIL ADDRESS:
STREET 1: 18000 STUDEBAKER RD
STREET 2: SUITE 800
CITY: CERRITOS
STATE: CA
ZIP: 90703
FORMER COMPANY:
FORMER CONFORMED NAME: DFP HEALTHCARE ACQUISITIONS CORP.
DATE OF NAME CHANGE: 20200108
8-K
1
toi-20230915.htm
8-K
toi-20230915
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.001
TOI
The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share
TOIIW
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
As previously reported, on April 25, 2023, The Oncology Institute, Inc. (the “Company”) received a written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the closing bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and that, as a result, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company was provided 180 calendar days, until October 23, 2023, to regain compliance.
On September 15, 2023, the Company received written notice from the Listing Qualifications Staff of Nasdaq notifying the Company that, for the last 11 consecutive business days, from August 30, 2023 through September 14, 2023, the closing bid price of the Company’s common stock was $1.00 per share or greater. Accordingly, the written notice stated that the Company has regained compliance with the minimum bid price listing requirement set forth under the Rule.
On September 18, 2023, the Company issued a press release announcing that it regained compliance with Nasdaq listing requirements.
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
The Oncology Institute Regains Compliance with Nasdaq Listing Requirements
CERRITOS, California, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) (the “Company”), one of the largest value-based community oncology groups in the United States, today announced that it received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) on September 15, 2023, informing the Company that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. This follows second quarter 2023 results demonstrating continued strong year over year revenue growth, and announcements on recent technology partnerships with Ambience Healthcare and Massive Bio to drive continued efficiencies and expansion of the business.
To regain compliance with the Rule, the Company’s common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. This requirement was met on September 14, 2023.
About The Oncology Institute, Inc.
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 800 teammates in over 65 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
EX-101.SCH
3
toi-20230915.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
0000001 - Document - Cover Pagelink:presentationLinklink:calculationLinklink:definitionLinkEX-101.DEF
4
toi-20230915_def.xml
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB
5
toi-20230915_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Document Period End DateDocument Period End DateCommon StockCommon Stock [Member]Pre-commencement Tender OfferPre-commencement Tender OfferClass of Stock [Domain]Class of Stock [Domain]Soliciting MaterialSoliciting MaterialCity Area CodeCity Area CodeEntity Address, Postal Zip CodeEntity Address, Postal Zip CodeEntity Central Index KeyEntity Central Index KeyEntity Address, City or TownEntity Address, City or TownSecurity Exchange NameSecurity Exchange NameTitle of 12(b) SecurityTitle of 12(b) SecurityWritten CommunicationsWritten CommunicationsDocument Information [Line Items]Document Information [Line Items]Local Phone NumberLocal Phone NumberTrading SymbolTrading SymbolEntity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeEntity Address, State or ProvinceEntity Address, State or ProvincePre-commencement Issuer Tender OfferPre-commencement Issuer Tender OfferCover [Abstract]Entity Emerging Growth CompanyEntity Emerging Growth CompanyRedeemable WarrantsWarrant [Member]Document TypeDocument TypeAmendment FlagAmendment FlagEntity Ex Transition PeriodEntity Ex Transition PeriodClass of Stock [Axis]Class of Stock [Axis]Document Information [Table]Document Information [Table]Entity File NumberEntity File NumberEntity Tax Identification NumberEntity Tax Identification NumberEntity Address, Address Line OneEntity Address, Address Line OneEntity Registrant NameEntity Registrant NameEX-101.PRE
6
toi-20230915_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
GRAPHIC
7
imagea.jpg
begin 644 imagea.jpg
MB5!.1PT*&@H -24A$4@ 7 !X" 8 #K/:GF @ $E$051XG.R]
MYY<<5W;M^;OWADN?6;X*!4^ "W(9G=3;=1.4DNM-S-/SZPU:^9?G#6SYNEI
M9%X[2=TT338] <(7"BB#\I4^(JZ9#S>RJN#8;)DG@LJ]5@%5D9'A,G+'N?N<
MLZ]PSCG&&&.,,<9XZB#_K0]@C#'&&&.,?QK&!#[&&&.,\91B3.!CC#'&&$\I
MQ@0^QAACC/&4(OBW/H!_/3AP%JP!!Z! "AP2)\!2+ :$ X%& )3O%N2BA G
M'MWL:)$XLO#HDU#B4 ^]\>'-?"[D[[7V&&.,\>\47V$"'T'\GNPY@D,YAWUX
M:X\E\,.U1D3NA#A\0GQ!C&E[C#'&^'WPU25PQR,$ZAZ_^)$EGD@M 1DX>;#*
MXPC[L1 2BP0A#M[S\#[%PTO=D1'!YV]]C#'&& /X*A,X@J,2OU\D:QXE9_^0$#A^CR2#>."_,<888XS?B:\N@1\H&$=)_''T
M>(1^!4=(7/"[X^9'XFB\ BX.-F,?6//A70J_YI$PW3V\[AACC#'&$_#5)? "
M!Y'W(R\ SL?*#L=A6M,=OOZ(VNV)W3VPK'C7P9^R>.OG"."CA\MCG@]C\AYC
MC#&^*+[B!/[XB'L4DUMK\6G*T8]_?10%"Q$\0.2>I!\7(Q]-6#J$[A((Z\
M_H3#8XV!NF:NT>OV\,Z2QQ&5".HB0%E)8BBP$?P.B<=#,BR(3I/
M?:N^,5AKP!J"4)%$94P8TLD=VDE4$%)M3G#LQ&G.7GB.8R?/4FJV$"K!B@#K
M)!I A$@5H(1".('XG KR,8&/,<88\!4B\(?)>_2[L5[S-GF*T4,B)1@.NJPM
M+_'1!^^Q=/LF.]O;2"69FIIB8GJ&X>W?8>>[L[]#IM=)[CC$%(1Y(D6.<8YII^9E!1F;G%DQP__0POOO9-
M:JT95*6&$Q'&"K1U"!$@54" XDDM0$*(,8&/,<88P%>8P ]/RU>98#72Y0Q[
M'6Y>^XSWWWV+VS>O4TIB3IXXSK'CB\S,S-":G*94JR'B*D&8^,H0(1#"H80K
MZD8L699B38KI=-C>6&=UY2[W5NZQ)='^#R=CAG 85X%1(9B2Y"R!,N'CI
M:QP[?8X3SURD/C6#=2&YL3@GD#(BE %C A]CC#%^%YX. C]ZA$_@K@/2MD4"
MT_E:;*$@'?:( D6OL\<[;_V:=]YZD^&@RXLO/,]SSUUDX?AQRHT&,@B1*L1F
M.;T<3%2AW4_I=CJDPR%*"$JED$H<$D7N,BO7/^;.
M1V^BTRY""H(X1BB%-F"=I-U+.77V/'_PW3_B](47<=4&UDIR)Q"$!P1^^ @J
MVOOQ1H4/FA7*1R_/%S15^9?U7GF2Y<"#Q_/P.&!
MOAEKK2=O:\'Z)AUQ4$]M<1B&69_N_CX___G/^.B#][EP\5DNO?(*B\=/4*[5
M$6&$$PW+*SWV9C:Y=VNTV:#M#6H;7#.I!*$0626 DB82C'BF:M2JM9IU*M
M$R41H)#Y@*T[UWGS5S_CLRL?8/(>E1@B9U%:D\B0S8T=%A:?X3L__M]8?.X5
MY,0,J5#DN2&2(2"1881V B<$2H"V&;$4!!PXMN (#EKWO5FN/=($^FCGZ%&7
MVU$U_$%%NK#%"@]21=&P^J#+ $>K'2V,;'B+"J##48(\TM_ZZ*A"XGATCU\$
MXK%-4*-#/#SXAU^UQ0K_M+W^2^!)7SCK++[+X+"9Z^A#5HW[!,9X"$\'@3_&
M4,0=M*/[*A#AG"=N!V:8@K&H0#!T*=U>A[_YZ[]FPB]) 04$H2
MA#$J3I!A0CD(:$2"87^7J]<^X/+';]/97";*!ZA!ES#5U$L-=MLII:E%OOV3
M_\C"\R]CRC6BN (6+ IDB!:"W/I$K$03"PK*!H?"$6"*"^,)W#OS*A]MQ!W_Z!R4<2E>^QMUOW1YXQCQ*X.K?$8'_
MKB^:#^>^@U8>>.?IV=YR&ER :&=W_[/KU!QJO?
M>)U77WV5N%PAS37WUC?9:7?9:W?9V^\PR'*"("(I)]3+)6::#8(X(HC+A'&)
M, Q]S3>&1#FDR7!Y1IZG:"MP4N%D2"0$@7*TJG-ER,JM_]-?!_B\.?(]JY.+3<.@)YR&F/C'I&Q"PX&A7BW ,^,!S$D(=D?32B
M_)?#HP+08[?_I//Y$F+T2=F'EHTQQI/P5!,X%%IW06!YEA%(B8ICK-9T>AT^
MOO()N^TVKW_[VSSW_(LX$9#JG#MKFZS=O\\PS\C2'"$$DXTZC6:#>JU*I5RB
M5:LBI0(5@2R^6,XAK"! $ 4A(@P0KH1QD%E!;OQ$$,+E9(,A45SB[,4726+%
M1T',TJ,0( XC+!'!EXC
MN>=@;#!.R@*'LM/CKH9\PO(Q_GWCJ2=P8PU"")24F%$D*@7]?I_;=Y:YO;3,
M:]_X!HO'3S(P@FZ_Q_KF-FN;FV@-CA 92"I)S.1$G9FI2>K5,E$8$'A%&>T<
MONE2()P#9S#.H(4AD,[[F@B%$@(KBN&NB@I?E1P9*DX]>XER7*55F^2CW[R)
M2 0#FY.(@&8C86/E.A^\H2@G"?.G7T2J!&,=PEG"("33^B"V/J##(F-Y5"NU
MQ>N'E'Z(AR-N\4@4>U3@/K+B0YP]VO:A^"8.K'J/'HWW6'_P_?]<0GKT
M^#]WY0)?_F[7+_\1CO%EP=-#X.+1/P]B3P=(01 $2 0ZS]GKM.D/AKQTZ146
M3Y[&.KB_MOTA2UGC* (]
MHY"/+4=Q1W\["+Z/O/<@LSG2VH\>TE&]O3@&]QB:/?CP_CD8I6&?_.J3"/Z?
M]@#YU]-BGG0\3_[L_B6V/L;3C*>#P!]W[SG/&THJM-;DUA"H ?TAT.$DBP<
M/\[LXB*]-*?3Z[.UUV%KOTM.@%(A4112KU68G6PPU:A2#@"; ]JWSQ<[.8@N
M'3Y9BH^,!1:L]CJP%865B8\ZK0-K'$()<"&YR4%5B%M57OG6]\FUX>8G[Y/J
M =*E1-+@AFWNW[G.O9M7>:;20"4UA(L0SJ$0*!02^R"1/J)U>\W\$".KW,-U
M#GGSL%+D:/0]>K<[\N]!WL^-%-I1M8L\LFT.B/HPA7GPQD<_Q@>>P/\)YJ
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M3^)VOX,,'U'>'[@7_&A+*7G@.(E0!P,",1JS/#1 $.ZHZ/3[08A15_WQ3A_\6^+IX/ GP3G;V:E%"H(< +O/AA%_N96DFX_X_[6#O>W=LB-148)
M4@A:C093$PTJY8B@N >E]-XE4CJ<]498N3'T,^/KP7.-LYIFK402*P;=-NMW
MEPF4("Q54&%,I=E"!2%A6-C%%ERA)2.$.F.> 3'TMOB=Q(01*'(GF
M1V3Y"%_Z>HO1]I\$(>0#)'_PNP,A'"9/D2)"2(DQ&JD<".D/38RNTD,*S^A<
MGG1;/43.1V&MWYJU]J K]N'NWR>1F@-L\1G*XH"DD _D"K36_CY4"IMK3]!A
MZ LUK44I]0\J'D]F/V;XPARS*BXKLQZI\0PANTC8GXZ<333> <1CY"
M"'*CR77N6Q65)#.6S=TV*VL;Y-H@"GUZLE%G=KI%)0X9-:TKO!P#BDQGZ"PC
M30VYANX@(S<68S2A$E1BA0L"NIU][MZ]S;#?)8Q+1$F9YN0T<;E,:W*":JU!
MG)0QVI%E6?'%#+$B0P4),R=/\_PK7^/]?]BAT^]1C6/0CJS?X?:U*RR>?9:%
MI(X, V2@L'A9QQF#PR%#!
M2$;ZBWI$87$C@<*AA$ *@?#Z$!AOS2NE*OS,11'U2JP9V?4>(9P#?7ZTMR\0
ML1XE[X=&8B;/B4*%D.",]O)2L8^C$OR#DI!?]KDSWCU$9D=M&OSK("18:S"Y
M]A;#4OG'G3LB)SUP'O[]QAAOBUG4=+NB]MO_#D'@KY?PLY!XD-R+EUBY=8.5:Y*XAA!>4Y=*
MXJ3T!%ITH&J= Z*0*A0H@; Y0AA_=L[B3$H01D@,2@F+)X31R_G_G+,Y:A/$$+MP1J49)I JPUJ#S#*G\Q!DC6<<5.QE)0 ?5*)\C
MD1V5* X^[X,$JBUR#(4>7T2BKI!T!-8W1'&XSR^*A_=[&&'[B-<80Y[G!Q&P
M"$"J423\I//Q.9$1*3OK/S\_X!$XZQ^2POE1C2JDK7PXQ D(X@AM-&@OZXV@
M=7X023_N-$>CA3 ,#Z24AZ_I&$\GGHJ*I<\?9'L8:[#.(E6 E(I!EK*QM<7N
M?I>H5$%(11P&S,],,EDO$TE+B"$2ED 8A#,X!P9%:@2]S)(YL$(APQ@5Q1 $
M&+RTX@ I+,(9E'#$D22)%)%RI,,NJZMWV=O?1N=#I#,$6#S7&$:-[UEN:,X=
MY^++WZ!4GR5S$4K%Q*%"V(REF]=I[^T@A7^X..NU#J]K%S&T%(1A0!0%**&!
M(;@!4J9(,42X 8(AH6M@D" \)BG<9A#PEQE&A\2%]P!7$;:[UU[JB;
M<63,(BU"FN*!H7$Z1><#L ;?D'DHE/B4JCAHOB\$"?B<'S^-W<._.V0@&?1Z
M]+H=G+-(*<#ZD9*U]K%\/4KG?J'[[H@T;#68HPA
M"(*#*%P(01S'8^GD*3$8%_3LY)"H%U#EW]/4@\Z6CZ(D?S?Z_48#H=$442E
M4CF(@#^/%!W>H]Y9A\1++Y[ 001A<6K&RU*99O7N71PP[2FII@[
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M>624-?8)18/)
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.